Drugs / BMS-911543
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01236352 | Apr 2011 → Nov 2015 | cancer | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-911543 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01236352 ↗ |
| Known as | ENSG00000096968 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545215 ↗ |
| Known as | JAK2 INHIBITOR BMS-911543 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545215 ↗ |
| Known as | JTK10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545215 ↗ |
| Known as | THCYT3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545215 ↗ |
| Action | Inhibit | “Tyrosine-protein kinase JAK2 inhibitor” CHEMBL3545215 ↗ |
| Modality | Small molecule | — CHEMBL3545215 ↗ |
| Route | Oral | “BMS-911543 5 mg capsule by mouth twice daily for 12 months or greater depending on response” NCT01236352 ↗ |
| Target | JAK2 | “Tyrosine-protein kinase JAK2 inhibitor” CHEMBL3545215 ↗ |